Overall Risk Group (1)
Primary Hazards (2)
Special Hazard Notes
(2)
Containment
Requirements (2)
Required PPE (2)
Spills outside BSC (2)
Effective
Decontamination (2)
Post Exposure
Information
Medical Surveillance
WSU Oversight
HELA Cell Line (HPV-18) Human Papilloma Virus-18
2
Exposure of mucous membranes to droplets/aerosols
Accidental parenteral inoculation
None
Biosafety level 2 practices and containment facilities for all activities involving
cell lines known to contain this virus.
Laboratory coat; gloves
Allow aerosols to settle: wearing protective clothing gently cover the spill with
absorbent paper towel and apply sodium hypochlorite to the spill, starting at
the perimeter and working towards the center; allow sufficient contact time
(30 min) before clean up
Sensitive to 1% sodium hypochlorite and 2% glutaraldehyde
There is no prophylactic treatment once an exposure has occurred. (2)
HPV-18 virus has been associated with the following diseases: Squamous cel
carcinoma of the sinuses, oral carcinoma, oral leukoplakia, squamous cell
carcinoma of the esophagus, Bowenoid papulosis, Bowen disease, Carcinoma
of the vulva, Carcinoma of vagina, Carcinoma of cervix, Carcinoma of the
penis. (4) HPV type 18 positive cervical cancer patients, despite negative
histological findings in the lymph nodes shoud be considerees as a
subpopulation for poor outcome especially in the young age group (5)
A vaccine is currently available. This vaccine is not effective post exposure.
All who work in labs that manipulate this agent are encouraged to become
informed as to the appropriateness of this vaccine for them. See references
for more information under (3) below.
1. Submit a BAF (Biosafety Approval Form) to the IBC (Institutional
Biosafety Committee). This form can be downloaded at the following
website: http://www.bio-safety.wsu.edu/forms.asp .
2. Obtain approval from the IBC before starting work.
3. Submit a current BSL-2 Biosafety Manual that includes an Exposure
Control Plan for Established Cell Lines to the WSU Biosafety Manager
by the submission deadline date. The BSL-2 manual template can be
downloaded from the following website: http://www.biosafety.wsu.edu/forms.asp .
4. You will be contacted by EH&S to schedule a facility review.
Note: The Biosafety Manual and the facility review need to be completed
prior to the IBC meeting or the BAF will likely be deferred until these reviews
have been satisfactorily completed.
1. HELA cell line WSU RG Risk Assessment located in this Biosafety Manual
2. http://www.phac-aspc.gc.ca/msds-ftss/msds85e-eng.php
3. http://caonline.amcancersoc.org/cgi/content/full/57/1/7
http://www.cdc.gov/std/Hpv/STDFact-HPV-vaccine.htm
Page | 1
http://www.gardasil.com/
http://www.cdc.gov/std/Hpv/STDFact-HPV-vaccine.htm
http://www.cancer.gov/cancertopics/factsheet/prevention/hbp-vaccine
4. http://www.emedicine.com/MED/topic1037.htm
5. http://cat.inist.fr/?aModele=afficheN&epsidt=1344446
Page | 2